GW572016 For Treatment Of Refractory Metastatic Breast Cancer

Sponsor

GlaxoSmithKline (Industry)

Overall Status

Completed

CT.gov ID

NCT00062686

Collaborator

(none)

200

Enrollment

Locations

Duration (Months)

28.6

Patients Per Site

1.9

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This study was designed to determine the efficacy of an oral dual kinase inhibitor for the treatment of metastatic breast cancer tumors that are known to overexpress ErbB2 in a refractory patient population.

Condition or Disease	Intervention/Treatment	Phase
Neoplasms, Breast	Drug: GW572016	Phase 2

Study Design

Study Type:

Interventional

Allocation:

Non-Randomized

Intervention Model:

Single Group Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

An Open-Label, Multicenter, Single Arm Phase II Study of Oral GW572016 as Single Agent Therapy in Subjects With Advanced or Metastatic Breast Cancer Who Have Progressed While Receiving HERCEPTIN-Containing Regimens

Study Start Date :

Nov 1, 2003

Actual Primary Completion Date :

Feb 1, 2005

Actual Study Completion Date :

Feb 1, 2005

Outcome Measures

Primary Outcome Measures

Tumor response rate []

Secondary Outcome Measures

clinical benefit rate time to progression 4 and 6 month progression free survival overall survival []

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

Female

Accepts Healthy Volunteers:

Inclusion Criteria:

Signed Informed Consent.
Histologically confirmed Stage IIIb or IV breast cancer.
Refractory breast cancer defined as progression in the metastatic setting after prior therapy with anthracyclines, taxanes and capecitibine.
Subjects with documented ErbB2 tumor overexpression must have received at least 6 cycles of trastuzumab.
Documented disease progression of the most recent treatment is required.
Archived tumor tissue available for testing.
Measurable lesions according to Response Evaluation Criteria In Solid Tumors (RECIST).
At least 3 weeks since prior cancer therapies except for trastuzumab which must be discontinued at least 2 weeks prior to the beginning of study drug.
Bisphosphonate therapy initiated prior to study entry is allowed, however, initiation of bisphosphonates following study entry is not allowed.
Able to swallow and retain oral medication.
Cardiac ejection fraction within the institutional normal range as measured by echocardiogram or MUGA (Multiple Gated Acquisition) scan.
Adequate kidney and liver function.
Adequate bone marrow function.

Exclusion criteria:

Pregnant or lactating.
Copies of nadir scans and/or photographs of the tumor prior to disease progression as well as scans documenting disease progression are not available for review.
Malabsorption syndrome, ulcerative colitis, disease significantly affecting gastrointestinal function or resection of the stomach or small bowel.
History of other malignancy.
Serious medical or psychiatric disorder that would interfere with the patient''s safety or informed consent.
Active or uncontrolled infection.
Known history of uncontrolled or symptomatic angina, arrhythmias or congestive heart failure.
Known history of or clinical evidence of leptomeningeal carcinomatosis.
Active infection.
Concurrent cancer therapy or investigational therapy.
Use of oral or IV steroids.
Unresolved or unstable serious toxicity from prior therapy.
Prior treatment with an ErbB1 and/or ERbB2 inhibitor other than trastuzumab.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	GSK Investigational Site	Buenos Aires		Argentina	C1455BWU
2	GSK Investigational Site	Villejuif Cedex		France	94805
3	GSK Investigational Site	Augsburg	Bayern	Germany	86150
4	GSK Investigational Site	Sutton	Surrey	United Kingdom	SM2 5PT
5	GSK Investigational Site	Bebington, Wirral		United Kingdom	CH63 4JY
6	GSK Investigational Site	London		United Kingdom	SW3 6JJ
7	GSK Investigational Site	Manchester		United Kingdom	M20 4BX